Collaboration intended to enable faster market delivery time for life-threatening disease medications.
Cognizant, an information technology (IT) company, and Gilead, a biopharma organization, announced a five-year expansion to their current partnership. As per the deal, Cognizant will manage Gilead's global IT infrastructure, platforms, applications and advanced analytics, and lead initiatives designed to accelerate its digital transformation, according to a company press release. The main goal of the partnership is to provide Gilead with the ability to streamline business in order to release medicines for life-threatening illnesses at a faster pace.
"We're excited about this expanded partnership with Gilead, one of the pharmaceutical industry leaders in adapting advanced technologies to better deliver transformative treatments for patients world-wide," said Surya Gummadi, EVP, President, Cognizant Americas. "Working together our teams will be leveraging the latest technologies from automation to cloud computing, and Generative AI to help Gilead bring its products to market faster, more efficiently, and with higher customer satisfaction."
References: Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million. PR Newswire. July 24, 2023. Accessed July 25, 2023. https://www.prnewswire.com/news-releases/cognizant-and-gilead-extend-partnership-with-five-year-service-agreement-estimated-at-800-million-301883522.html
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.